CTLA4 and neoplasm: ICI therapy represented by PD-1 and CTLA-4 inhibitors has undoubtedly caused a breakthrough in anti-tumour therapy (Topalian et al., 2016; Darvin et al., 2018; Kalbasi and Ribas, 2020).